Back to Search Start Over

United European Gastroenterology (UEG) and European Society for Neurogastroenterology and Motility (ESNM) consensus on gastroparesis

Authors :
George Karamanolis
Trygve Hausken
A. Sheptulin
A Papathanasopoulos
Jan Tack
Daniel Keszthelyi
M. Corsetti
T. Milosavljevic
Frank Zerbib
M. Storr
Dan L. Dumitrascu
A. Stengel
Hans Törnblom
Tim Vanuytsel
Giovanni Sarnelli
C. Malagelada
H. De Schepper
Lucas Wauters
Daniel Pohl
Agata Mulak
Ram Dickman
Goran Hauser
D. Rumyantseva
Giovanni Barbara
Jordi Serra
N. Zarate
C. O'Morain
Benoit Coffin
Guillaume Gourcerol
Anne Farmer
Serhat Bor
Vasile Drug
M. Velosa
Annemieke Smet
Edoardo Savarino
Jolien Schol
Paul Enck
M. Waluga
Anna Accarino
O. Storonova
Sarnelli, G.
Schol J.
Wauters L.
Dickman R.
Drug V.
Mulak A.
Serra J.
Enck P.
Tack J.
Barbara G.
Interne Geneeskunde
RS: NUTRIM - R2 - Liver and digestive health
MUMC+: MA Maag Darm Lever (9)
Source :
United European Gastroenterology Journal, Volume 9, Issue 3, United European Gastroenterology Journal, 9(3), 287-306. SAGE Publications Inc.
Publication Year :
2021
Publisher :
JOHN WILEY & SONS LTD, 2021.

Abstract

BACKGROUND: Gastroparesis is a condition characterized by epigastric symptoms and delayed gastric emptying (GE) rate in the absence of any mechanical obstruction. The condition is challenging in clinical practice by the lack of guidance concerning diagnosis and management of gastroparesis. METHODS: A Delphi consensus was undertaken by 40 experts from 19 European countries who conducted a literature summary and voting process on 89 statements. Quality of evidence was evaluated using grading of recommendations assessment, development, and evaluation criteria. Consensus (defined as ≥80% agreement) was reached for 25 statements. RESULTS: The European consensus defined gastroparesis as the presence of symptoms associated with delayed GE in the absence of mechanical obstruction. Nausea and vomiting were identified as cardinal symptoms, with often coexisting postprandial distress syndrome symptoms of dyspepsia. The true epidemiology of gastroparesis is not known in detail, but diabetes, gastric surgery, certain neurological and connective tissue diseases, and the use of certain drugs recognized as risk factors. While the panel agreed that severely impaired gastric motor function is present in these patients, there was no consensus on underlying pathophysiology. The panel agreed that an upper endoscopy and a GE test are required for diagnosis. Only dietary therapy, dopamine-2 antagonists and 5-HT4 receptor agonists were considered appropriate therapies, in addition to nutritional support in case of severe weight loss. No consensus was reached on the use of proton pump inhibitors, other classes of antiemetics or prokinetics, neuromodulators, complimentary, psychological, or more invasive therapies. Finally, there was consensus that gastroparesis adversely impacts on quality of life and healthcare costs and that the long-term prognosis of gastroparesis depends on the cause. CONCLUSIONS AND INFERENCES: A multinational group of European experts summarized the current state of consensus on definition, symptom characteristics, pathophysiology, diagnosis, and management of gastroparesis. ispartof: UNITED EUROPEAN GASTROENTEROLOGY JOURNAL vol:9 issue:3 pages:287-306 ispartof: location:England status: published

Details

Language :
English
ISSN :
20506406 and 20506414
Database :
OpenAIRE
Journal :
United European Gastroenterology Journal, Volume 9, Issue 3, United European Gastroenterology Journal, 9(3), 287-306. SAGE Publications Inc.
Accession number :
edsair.doi.dedup.....01faf1a29acaef013f672c09fd88620a